| Formulation |
IL17RB protein solution (0.25mg/ml) containing phosphate buffered saline (pH 7.4) and 10% glycerol. |
| Purity |
Greater than 85.0% as determined by SDS-PAGE. |
| Description |
IL17RB Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 514 amino acids (18-292a.a) and having a molecular mass of 57.2kDa (Migrates at 50-70kDa on SDS-PAGE under reducing conditions).IL17RB is fused to a 239 amino acid hIgG-His-tag at C-terminus & purified by proprietary chromatographic techniques. |
| Protein Background |
IL17 is a proinflammatory cytokine produced by activated T cells. IL-17 regulates the activities of NF-kappaB and mitogen-activated protein kinases. Interleukin-17 can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. |
| Expression host |
Escherichia Coli. |
| Synonyms |
Interleukin 17 Receptor B, IL17RH1, IL17BR, Interleukin 17B Receptor, Cytokine, Receptor-Like 4, Interleukin-17B Receptor, IL-17 Receptor Homolog 1, IL-17 Receptor B, IL-17B Receptor, IL-17Rh1, IL-17RB, EVI27, CRL4, Interleukin 17 Receptor Homolog 1, Interleukin-17 Receptor B, Cytokine Receptor CRL4. |
| Reagent Appearance |
Sterile Filtered clear solution. |
| Stability |
Store at 4°C if entire vial will be used within 2-4 weeks.Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. |
| Amino acid sequence |
REPTVQCGSE TGPSPEWMLQ HDLIPGDLRD LRVEPVTTSV ATGDYSILMN VSWVLRADAS IRLLKATKIC VTGKSNFQSY SCVRCNYTEA FQTQTRPSGG KWTFSYIGFP VELNTVYFIG AHNIPNANMN EDGPSMSVNF TSPGCLDHIM KYKKKCVKAG SLWDPNITAC KKNEETVEVN FTTTPLGNRY MALIQHSTII GFSQVFEPHQ KKQTRASVVI PVTGDSEGAT VQLTPYFPTC GSDCIRHKGT VVLCPQTGVP FPLDNNKSKP GGWLPVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGKHH HHHH. |
| Specifications |
Performed by mixing equimolar amounts of cytokeratins of type I and type II at concentrations of approx. 0.5 mg/ml, both dissolved in 9.5 M urea buffer (see above). Protofilaments and filament complexes are obtained by dialyzing the resulting polypeptide solution stepwise to a concentration of 4 M urea and then to low salt condition (50 mM NaCl, 2 mM dithiothreitol, 10 mM Tris-HCl, pH 7.4). For immunization purposes, the solution can be further dialyzed against PBS (phosphate buffered saline, e.g. Dulbecco's PBS). |
